In recent years, the diabetic macular edema (DME) market is anticipated to grow rapidly during the forecast period. Diabetic macular edema (DME) is characterized by fluid accumulation in the macula, which is the region of the retina important for vision. Edema can result from the leakage of plasma contents into the surrounding area, causing the accumulation. Diabetic macular edema is one of the primary causes of blindness in diabetic patients, affecting around 12% of type 1 diabetes patients and 28% of type 2 diabetic patients in developing nations in 2011. Controlling blood sugar levels, or glycaemia, lipid levels, and renal function is the conventional treatment for diabetic macular edema. The Diabetes Control and Complications Trial (DCCT) found that individuals who received aggressive glycaemic treatment had a 2.3 percent lower risk of DME.
